



Published in final edited form as:

J Int Neuropsychol Soc. 2013 April ; 19(4): . doi:10.1017/S1355617712001634.

Isolating Cognitive and Neurologic HIV Effects in Substance-Dependent, Confounded Cohorts: A Pilot Study

Desiree A. Byrd¹, Jessica Robinson-Papp¹, Monica Rivera Mindt^{1,2}, Letty Mintz¹, Kathryn Elliott¹, Quenesha Lighty³, and Susan Morgello¹ for the Manhattan HIV Brain Bank

¹Department of Neurology, Mount Sinai School of Medicine, New York, New York

²Department of Psychology, Fordham University, New York, New York

³Department of Psychology, the City University of New York, New York, New York

Abstract

Controversy exists as to whether effects of HIV infection can be detected in the cognitive profiles of substance users, with methodological differences in degree of control for confounding factors a major contributor to empirical discrepancies. To address this shortcoming, we conducted a small but well-controlled study aimed at isolating HIV neurocognitive (NC) effects in a group of chronic substance users. Thirty HIV-negative substance users were individually matched to 30 HIV-positive substance users on relevant medical and demographic factors, including reading level and methadone therapy status. Results revealed that reading level, methadone maintenance therapy, and positive urine toxicology each exerted significant influence on NC function, and that HIV status was a significant predictor of learning and speeded processing after these control factors were considered. The HIV-positive group also displayed significantly more neurologically assessed motor impairment ($p < .05$), which was specifically related to impaired cognition in this group and independent of degree of immunocompromise. These data demonstrate the need for increased attention to clinical/demographic characteristics of groups under study. They also show that with applied methodological rigor, the deleterious effects of HIV on cognition can be parsed from substance use, even in small samples with chronic and active use histories.

Keywords

Cognition; AIDS; neuropsychological tests; illicit drugs; confounds; motor dysfunction

Introduction

The interpretation of findings from clinical neuroAIDS research is complicated by the myriad of confounding and comorbid conditions that HIV-positive (HIV+) patients often present with, such as head injuries, other central nervous system (CNS) -relevant medical conditions, and substance use (Heaton et al., 2010; Martin-Thormeyer & Paul, 2009; Wojna & Nath, 2006). As such, it has been difficult to draw definitive conclusions regarding the etiological source of neurocognitive deficits from individual studies of complicated HIV+ cohorts. Furthermore, the motoric abnormalities traditionally observed in HIV associated

neurocognitive disorders (HAND) have not yet been demonstrated to be definitively HIV-related and occurring independently from confounds and comorbid conditions.

One of the most compelling confounding factors in neuro-AIDS research is substance use (Gonzalez & Cherner, 2008). It is estimated that upward of 81% of persons living with HIV/AIDS have used illicit substances in their lifetime, and many have comorbid substance use disorders, which are often chronic and involve multiple substances (Bing et al., 2001; Burnam et al., 2001; NIDA, 2011). The neurobiologic and neuroimaging literatures in both HIV+ and seronegative samples firmly establish the neurotoxic impact of substances such as alcohol, cocaine, and opiates (Buttner, 2011; Friedman, Newton, & Klein 2003; Lundqvist, 2010; Venkatesan, Nath, Ming, & Song, 2007). Likewise, many neurocognitive studies in the general population report performance decrements in substance users across an array of cognitive domains, but particularly those purportedly sub-served by frontal-striatal circuitry (Fernández-Serrano, Pereéz-García, Río-Valle, & Verdejo-García, 2010; Gruber, Silveri, & Yurgelun-Todd, 2007; Kalechstein & van Gorp, 2007; Scott et al., 2007). However, neurocognitive research in substance-using HIV+ cohorts has produced mixed findings. Studies that predate the use of highly active antiretroviral therapy (HAART), surprisingly, failed to uncover significant effects of HIV infection in cohorts of active substance users, despite the generally advanced nature of inadequately treated HIV disease (Concha et al., 1992, 1997; Durvasula et al., 2000; Selnes et al., 1997). Results from HAART-era investigations have varied by the substance being examined and the design of the study. Byrd et al. (2011), with an exclusively HIV+ sample (the CHARTER cohort), did not detect any effect of substance use on neurocognition when comparing groups of HIV-infected adults who varied in substance use histories. However, other investigators, who have included comparable HIV-negatives in their study designs, have reported significant effects of HIV status and sometimes, substance use, on cognition (Chana et al., 2006; Martin et al., 2003; Rippeth et al., 2004). Nevertheless, the HIV effect in HAART-era substance users remains unclear, as others have failed to detect a detrimental effect on cognition (Basso & Bornstein, 2000; Devlin et al., 2012; Durvasula et al., 2000; Gonzalez & Cherner, 2008; Martin-Thormeyer & Paul, 2009).

Currently, it is unclear whether the lack of consistency regarding the use of illicit substances and cognition within the neuroAIDS literature is due to methodological differences or related to truly varied patterns of neurocognitive substance impacts within HIV infection. Because intravenous use of opiates is a primary disease transmission mechanism, intravenous drug users (IVDUs) have been among the most studied substance using HIV+ group (Bell, Arango, & Anthony, 2006; Bell, Brettle, Chiswick, & Simmonds, 1998; Concha et al., 1992; Selnes et al., 1997). One shortcoming of many neurocognitive studies of HIV+ IVDUs has been the lack of attention to methadone maintenance treatment status. This opioid replacement therapy has been demonstrated to exert significant detrimental effects on motor speed, working memory, decision making, and metamemory, yet its potentially confounding influence in studies of neurocognition in HIV has largely been overlooked (Darke, McDonald, Kaye, & Torok, 2012; Mintzer & Stitzer, 2002; Soyka et al., 2008). Similarly, studies in this area have been inconsistent in the control of other important confounding factors that could dilute results. For example, despite the demonstrated importance of reading level to cognitive test performance and differences among substance users on reading level, few studies have examined and controlled for this factor. Additional methodologic oversights include total reliance upon self-report of drug use for categorization into drug groups (absence of urine toxicology), and little to no attention to hepatitis C status or distal sensory polyneuropathy. Finally, cognitive studies are often done in disciplinary isolation and rarely combined with neurologic examinations to expand the understanding of these complicated cohorts, and to determine if objective CNS dysfunction, such as motor impairment, is impacting observed relationships.

Historically, motoric abnormalities (e.g., hyperreflexia, motor slowing, gait disturbance, limb incoordination, hypertonia) were considered a central component of the manifestation of central nervous system dysfunction in HIV-infection (Janssen, Cornblath, Epstein, & Foa, 1991; Navia, Jordan, & Price, 1986). In fact, motor dysfunction was included among the diagnostic criteria for HIV-associated dementia (Janssen et al., 1991). Recently, motor abnormalities were shown to be related to HAND in a HAART-era cohort (Robinson-Papp et al., 2008). However, no studies have examined the specificity of the neurologically assessed motoric impairments to HIV in complicated cohorts with other risk factors for motor abnormalities, such as substance use. For example, there is marked increased risk for neurologic abnormalities in chronic substance use for neuropathy, ataxia, stroke, cerebral volume reduction, and white matter hyperintensities (Brown, Prager, Lee, & Ramsey, 1992; Koike et al., 2003; Liu et al., 2009; Neiman, Haapaniemi, & Hillbom, 2000; Richter et al., 1973; Welch, 2011; Yeung, Bhalla, & Birns, 2011). It is not known whether the motoric symptoms of HIV might also occur in seronegative chronic substance users and the degree to which such neurologically determined symptoms might be associated with neurocognition.

In the current pilot study, we applied rigorous matching criteria to a group of chronic substance using adults, who differed on HIV status, in an effort to increase the understanding of the intersection of substance use and HIV infection on cognitive and motoric functioning. We used a comprehensive cognitive battery used in large HAART-era cohorts (Woods et al., 2004), and the HIV Dementia Motor Scale (Robinson-Papp et al., 2008) to test whether neurologically assessed motor abnormalities were related to HIV and cognitive functioning. We used an ethnically diverse, urban sample of chronic substance users and hypothesized that impairments in cognitive domains subserved by frontal subcortical circuitry, traditionally impacted by HIV infection, would be detected in the HIV + group and that this group would demonstrate motoric abnormalities that are uniquely associated with compromised cognition.

Methods

Participants

Baseline data for HIV+ ($n=30$) participants was abstracted from the Manhattan HIV Brain Bank (MHBB U01MH083501), a longitudinal observational, organ donation study of advanced HIV disease that includes biannual neurologic, neuropsychologic (NP), and psychiatric examinations (Morgello et al., 2004). The HIV+ participants selected for this study were comparable to the unselected HIV+ participants in the MHBB in age, education, gender, reading level, and degree of immune compromise (p values for all comparisons $>.10$). HIV-negative (HIV-) participants ($n=30$) were recruited specifically for the purposes of this analysis, and were not from the MHBB study. Recruitment occurred primarily through advertisements at methadone maintenance clinics, medical centers, and local businesses in East Harlem, New York. All participants were primarily English-speaking. Participants were excluded from this study if they had signs of distal sensory polyneuropathy (DSP) in their hands, history of stroke or opportunistic infection, hearing, vision, or motor impairment which impeded the completion of the NP battery, active psychosis, or no history of chronic substance use. HIV- status was confirmed via Western blot. This study was approved by the Mount Sinai School of Medicine Institutional Review Board.

Procedure and Measures

The following assessments were completed for all participants: neuromedical examination, including blood samples for laboratory and virologic determinations; neurologic examination; neuropsychological testing; and a diagnostic psychiatric interview.

Neuromedical/Neurologic Examination

The neuromedical examination included the collection of a detailed medical history and a structured medical evaluation. Collected blood samples were tested for hepatitis C antibodies, CD4+ lymphocyte counts and HIV load (for HIV+ participants), and the presence of HIV antibodies by Western Blot (for HIV-negatives). Urine toxicology screened for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine, methadone, and propoxyphene. Illicit status was determined by review of prescribed medications. Participants with positive urine toxicology were not excluded from study but were rescheduled if they presented as behaviorally intoxicated. Methadone maintenance status was confirmed by the detection of methadone metabolites in the urine. Participants underwent a standard neurologic examination conducted by a board certified neurologist.

Neurocognitive Test Battery

Participants were administered a battery of neuropsychological tests that assessed a broad range of cognitive abilities sensitive to HIV impairment (Woods et al., 2004). Specific tests and their normative references are listed in Table 1. All individual tests were grouped according to the theoretically derived domains indicated in Table 1 (Woods et al., 2004). Raw scores from all tests were converted to demographically adjusted *T*-scores that adjusted performance for the effects of age, education, sex, and ethnicity, where appropriate. Domain scores were derived from the mean *T*-scores of the individual tests in that particular domain, and the global score is the mean of all individual neuropsychological test *T*-scores.

Substance Use Assessment

The Psychiatric Research Interview for Substance and Mental disorders (PRISM), a semi-structured clinical interview, was used to assess the presence of substance use disorders (abuse and dependence) using DSM-IV diagnostic criteria (Hasin et al., 1996). Past disorders are defined as having occurred before the last 12 months, whereas current disorders occurred within the last 12 months. As mentioned above, urine toxicology was used to determine shorter-term, acute substance use.

Motor Functioning

The HIV-Dementia Motor Scale (HDMS) was used to measure the presence and severity of motor abnormalities (Robinson-Papp et al., 2008). The HDMS uses elements of a standard neurologic examination to assess five motor domains: strength, tone, reflexes, coordination, and gait. The following assessments are performed in each limb: manual muscle strength testing of a proximal and distal muscle, motor tone, and a deep tendon reflex. In addition, an overall assessment of coordination and gait is made, and the presence of pathological reflexes (snout, glabellar, and extensor plantar response), is determined. A total score ranging from 0–20 is calculated with higher scores reflecting more motor abnormalities. The HDMS was developed and validated in HIV-infected populations (Robinson-Papp et al., 2008); before this study, it has not been examined in HIV-negatives.

Matching Procedures

HIV-negatives were individually matched, to the degree possible, to HIV+ participants who were selected from the pool of MHBB subjects with baseline NP and psychiatric data ($n =$

355). The matching factors were selected based upon studies which identified variables relevant to NP test performance in HIV-infected samples and/or in normative samples (Byrd et al., 2011; Ryan et al., 2005; Verdejo, Toribio, Orozco, Puente, & Pérez-García, 2005). Our matching process was based upon WRAT-3 Reading subtest scaled score, urine toxicology result, gender, status for current methadone maintenance therapy and hepatitis C serostatus.

Data Analysis

Demographic and medical characteristics were compared using *t* tests or Pearson's χ^2 tests, as appropriate. Multiple regression analyses were used to determine whether HIV status accounted for a significant amount of the variance in each of the NC domains and the global score after the variance associated with the clinical/demographic variables of interest (reading level, hepatitis C status, methadone maintenance therapy status, and positive urine toxicology results) had been accounted for. As the focus of this analysis was on the neurocognitive impact of HIV, we did not examine whether the clinical/demographic variables of interest exerted influence in an independent or interactive manner. Thus, these variables were entered together into multiple regression analyses at step one, and HIV status entered independently at step 2. Multi-collinearity diagnostics were also calculated with the use of variance inflation factor (*VIF*) values and tolerance levels. Data from the HDMS were log10 transformed before analyses to correct for the extreme positive skew in the distribution of these data. Mann-Whitney *U* tests were used to compare HDMS scores between HIV+ and HIV- groups. Because HDMS has only been previously validated in HIV, to examine whether it was associated with neurocognition, we conducted separate analyses of variance/analyses of covariance (ANOVA/ANCOVAs) within each HIV grouping.

Results

Clinical Characteristics

As planned with the matching procedure, the HIV+ and HIV- groups were similar in age, education, gender, ethnicity, reading level, proportion with hepatitis C, urine toxicology positive for illicit substances, and methadone maintenance therapy (all *p* values >.05; see Table 2). For the HIV+ group, the median CD4 count was 166 with a range of 1–1,308 and 25% had an undetectable viral load.

Substance Use Characteristics

Twenty-nine of the 30 HIV-negatives met DSM-IV diagnostic criteria for lifetime dependence on at least one substance, and one seronegative participant failed to meet diagnostic criteria but admitted to long-term chronic cocaine use (17 years of near daily use of crack and/or cocaine yet denied any functional impact of this use pattern) and had a positive urine toxicology result for cocaine. All 30 HIV+ persons had a lifetime diagnosis of substance dependence on at least one substance. Polysubstance histories characterized most participants in this study as only 13% met criteria for dependence on a single substance alone while 10% met criteria for dependence on four substances. The most commonly diagnosed disorders were for misuse of combinations of alcohol, cocaine, opiates, and marijuana. The HIV+ and HIV- groups were fairly split on the recency of substance use: 40% of HIV- and 48% of the HIV+ group met criteria for past use only. The remaining proportions either met criteria for current use or had positive urine toxicology for illicit substances. Of note, 41% of HIV+ and HIV- participants with positive urine toxicology failed to meet criteria for a current dependency diagnosis for that substance. Details regarding the rate of dependency diagnoses for each class of substance are presented in Table 3.

Neurocognition

Group mean performances are displayed in Table 4. A series of stepwise linear multiple regression analyses were performed to determine the ability of HIV status to predict NC functioning after the variance associated with clinical variables was accounted for. Tables 5a–5c illustrate the results of each of the multiple regression analyses. Among the control variables entered at the first step (reading level, hepatitis C infection, methadone treatment status, and urine toxicology), reading level was the strongest and the most consistent predictor of NC functioning for all domains with the exception of motor (all beta values significant at or below the .05 level). When considered simultaneously with other control variables, current methadone treatment emerged as a significant predictor of poorer learning ($p < .05$), recall ($p < .05$), and verbal fluency ($p < .05$), and at the trend level, poorer global function ($p < .10$). Positive urine toxicology predicted better performance in learning ($p < .05$) and, at the trend level, predicted improved working memory ($p < .10$) and recall ($p < .10$). In contrast, hepatitis C infection was not a significant predictor of performance in any of the domains. After accounting for the set of control variables entered at step 1 of the analyses, HIV infection predicted worse NC functioning globally and in several individual domains. The overall model predicting Global NP functioning accounted for 42% of the variance ($R^2 = .417$; $F_{(5,49)} = 7.01$; $p < .0001$) and the increase in R^2 associated with the addition of HIV status to the model was significant ($p < .05$). HIV status was also a significant predictor of processing speed, ($R^2 = .232$; $F_{(5,49)} = 2.96$; $p = .02$), learning ($R^2 = .455$; $F_{(5,49)} = 8.18$; $p < .0001$) and the increase in R^2 associated with the addition of HIV status to the models was significant ($p < .05$). For all other domains, HIV status did not significantly increase the models' predictive power.

To explore whether the lower processing speed and learning performances associated with HIV infection were related to the overall severe compromised immune status of this group, we ran bivariate correlations between these factors. Results indicate that performance on tests of processing speed and learning were not significantly correlated with current CD4 count (Spearman's $r(30) = .26$ and $.19$, respectively, both p values $> .10$).

Motor Functioning

HIV-negatives did not demonstrate as many of the motoric abnormalities measured by the HDMS as HIV-positives. While 47% of the HIV- sample demonstrated some motoric abnormality, the maximum score earned by a seronegative participant was only 2. As expected, a higher proportion of HIV+ participants earned a score of 1 or more (67%) on the HDMS. This group demonstrated a greater range of impairment (up to 12 points on the HDMS) and earned a significantly higher median score on this scale (Mdn=1) than the HIV- group (Mdn = 0; $U=296.5$; $p=.017$). To better characterize the nature of motoric abnormalities in each group, we examined the rate of abnormalities (a score of 1 or more) in each respective subscale of the HDMS. As reflected in Table 6, HIV infected participants demonstrated abnormalities in all domains assessed by the HDMS with reflex abnormalities being most common, appearing in approximately half of all persons with HIV. For the HIV- group, where abnormalities were rare, when they were present, reflex abnormalities were most common, appearing in a third of the entire group.

To investigate possible associations between neurologically assessed motor dysfunction and cognition, separate analyses were completed for the HIV+ and HIV- groups comparing persons with some evidence of motor dysfunction (HDMS ≥ 1) to those with no motor dysfunction, using ANOVA/ANCOVA, as appropriate (see Table 7a and b). Motor abnormalities were related to cognition only within the HIV positive group. For the HIV- group, no significant differences in cognitive domain scores were observed between the neurologically assessed motor impairment groups (all p values $> .10$). Among HIV+

participants, we first compared the motor impaired ($n=10$) and motor normal groups ($n=10$) on CNS relevant disease (viral load, CD4 count), demographic (age, gender, ethnicity, WRAT-3 reading score) and urine toxicology parameters to determine the need for the inclusion of any covariates in subsequent analyses. *T*-tests revealed a trend for the motor normal group to have higher WRAT-3 reading test scores than the motor impaired group ($t(28) = -.192$; $p = .065$). Thus, this test was used as a covariate in subsequent analyses. No other significant differences were observed among the parameters (all other p values $> .10$). For cognitive test performance, results from ANCOVA revealed that the HIV+ motor impaired group performed significantly worse than the HIV+ motor normal group on processing speed ($F(1,27) = 10.68$; $p = .003$), fluency ($F(1,27) = 6.48$; $p = .02$), and abstraction ($F(1,27) = 7.48$; $p = .01$). There was a trend for the motor impaired group to earn lower scores in the cognitive motor domain ($p = .07$). Thus, the relationship between neurologically assessed motor dysfunction and cognition was specific to the HIV positive group.

Discussion

The results of this pilot examination revealed that in a small but well controlled sample, it was possible to detect a deleterious effect of HIV on cognition in the context of chronic polysubstance use and dependence. Additionally, we observed that, among substance users with HIV, the presence of neurologically assessed motoric abnormalities, as measured by the HDMS, was related to worse cognition, whereas no such association existed among the seronegatives, indicating selectivity for the relationship between neurologically assessed motor abnormalities and impaired cognition in HIV infection.

The finding of HIV-related cognitive impairment in this complex advanced HIV sample confirms the persistence of detrimental cognitive effects of HIV in post-HAART era substance users and is consistent with larger studies of neurocognition in generalized, non-substance abuse specific HIV+ samples (Heaton et al., 2010). What is unique about the finding of an HIV-related NP effect among chronic substance users is that it stands in contrast to reports from some similarly designed pre- and post-HAART studies of chronic substance using groups that failed to detect worsened neurocognition with HIV infection (Basso & Bornstein, 2003; Concha et al., 1992, 1997; Del Pesce et al., 1993; Durvasula et al., 2000; Levine et al., 2006). For example, a recent study of HIV+ and seronegative polysubstance users did not find an effect of HIV serostatus on cognition though HCV status and HIV-related disease parameters were associated with cognitive dysfunction (Devlin et al., 2012). A reasonable conclusion from the collection of prior negative findings is that, in the setting of substance use, HIV infection does not exert additional damage to cognition. However, our results, obtained through a methodologically rigorous pilot study, reveal that HIV infection does in fact exert negative effects on cognition in chronic substance users and that these effects can be detected with increased methodological precision. Our findings highlight the need for greater attention to the degree to which HIV+ and seronegative samples differ on important, potentially confounding parameters before the drawing of conclusions across neurocognitive studies.

The current HIV+ sample earned significantly lower scores on tests of processing speed and encoding than the seronegatives, even after accounting for methadone status, reading level, hepatitis C, and positive urine toxicology results. The observation of an HIV effect on tests requiring rapid processing of information and encoding new information is consistent with the classic conceptualization of HIV as a subcortical disease targeting frontal-striatal circuits supporting these abilities (Baldewicz et al., 2004; Llorente et al., 1998; Reger, Welsch, Razani, Martin, & Boone, 2002). The absence of a significant difference in neuropsychologically assessed fine motor speed was unexpected, given that slowed motoric

response has been established as a corner stone of the cognitive profile of HIV infection (Reger et al., 2002). The absence of a motor speed finding could be due to several reasons. It is possible that the HIV effect on fine motor speed is less robust than other domains and that the small size of this pilot study yielded decreased power to detect milder differences. It is also possible that prior reports of slowed motor speed, as measured by neuropsychological tests, have been exaggerated by the unmeasured yet confounding impact of factors such as DSP and/or methadone usage (Fellows et al., 2012). Notably, the current study excluded persons with DSP and matched the HIV+ and seronegative groups on methadone status, eliminating the potential for these conditions to confound results. These two factors have been demonstrated to detrimentally impact fine motor speed in HIV+ populations (Fellows et al., 2012; Mintzer & Stitzer, 2002; Soyka et al., 2008) and removing the variance associated with these factors likely made any additional HIV-related differences less discernible, particularly in this small sample.

The neurologically assessed motor abnormalities in strength, tone, coordination, and gait were practically absent in the seronegatives, despite chronic substance use histories, affirming their specific association with HIV infection in this sample and demonstrating their relative independence from substance use. When motoric abnormalities were present in HIV-negatives, they were most likely to be related to abnormal reflexes than other areas of motor functioning, which may be a sign of cortical damage resulting from chronic substance use (Yuan et al., 2009). To our knowledge, our study is the first report of an examination of this potential relationship in seronegative substance users. Neurologically assessed motor dysfunction was related to impaired cognition among participants with HIV but not the seronegatives. The fact that the association was specific to HIV infection suggests that similar neurologic substrates subservise cognition and motor functioning in HIV and that, to the degree possible, results from cognitive and neurologic examinations should be considered together; when impairment is observed in both areas, clinicians might gain confidence in attributing the etiology of the dysfunction to HIV versus a confounding factor, such as substance use. Thus, we believe that information on motoric functioning using a scale such as the HDMS can aid in HIV neurodiagnostics. Furthermore, the HDMS has the advantage of being free from the cultural confines and potential biases of cognitive testing.

Taken together, these findings, while preliminary, highlight important considerations for the design of clinical research studies exploring the cognitive effects of HIV and substance use in complex cohorts. The current study adds to the growing literature on substance use and cognition in the HAART era and was strengthened by correspondent neurologic examinations on all patients, allowing the simultaneous evaluation of cognitive and neurologic functioning. This study avoided the interpretive confusion from confounding factors through extensive measurement and one-to-one matching of HIV positive and seronegative persons. In fact, the measurement of potentially confounding variables and the examination of their empirical association with neurocognition revealed important relationships that have the potential to impact the results of future neuroAIDS research. First, WRAT reading scores were the strongest predictors of cognitive test performance in practically all NC domains. This finding is consistent with many prior reports of the robust relationship between NC tests and reading ability and confirms the critical importance of assuring comparable reading levels across groups being compared in HIV studies so as to not misattribute performance differences to the factor of interest rather than reading level (Manly et al., 1998, 2004; Ryan et al., 2005).

Second, evidence of very recent illicit substance use, measured *via* urine toxicology results, was significantly related to improved performance in learning and trended toward better performance in working memory and recall. Controlled human research on the cognitive effects of acute intoxication is quite limited given the methodologic and ethical difficulties

associated with the execution of such studies. Nonetheless, neurobiologic and neuroimaging research on the toxic impact of substances of abuse on CNS structure and function, yields the general expectation of a performance decrement secondary to exposure (Poon, Abdullah, Mullan, & Crawford, 2007; Schlaepfer et al., 2006). However, our observation of a performance “benefit” in select domains in this pilot study lies in contrast to this expectation yet is not completely novel, given the high rate of stimulant use in our sample (82% of HIV+ and HIV- persons with a positive urine toxicology had evidence of recent cocaine use) and established research on the neuroactivating properties of this specific class of substances (Garavan, Kaufman, & Hester, 2008; Pace-Schott et al., 2008; Wiegmann, Stanny, McKay, Neri, & McCardie, 1996). Also noteworthy is the degree of discrepancy between self-report of substance use and urine toxicology results in this sample. Of those with a positive urine toxicology, 41% did not meet a current dependency diagnosis for that substance, highlighting the added benefit of urine toxicology tests in neuroAIDS substance abuse research (Reinhard et al., 2007).

Finally, we also found that current treatment with methadone, an opioid replacement therapy, was predictive of performance decrements in learning, memory, and verbal fluency. This finding supports prior research documenting the detrimental neurocognitive effects of methadone (Mintzer, Copersinok, & Stitzer, 2005; Verdejo et al., 2005). For example, Darke et al. (2012) reported that opioid maintenance therapies exerted a significant performance decrement in processing speed, learning, memory, and executive functioning and that this finding was separable from the effects of long-term heroin use without maintenance therapy. Considering the high rate of methadone maintenance therapy in HIV-infected samples (CDC, 2007), this factor deserves increased consideration in studies using data from participants treated with this therapy. Also important to consider, though not able to be explored in the current study, is the dosage and length of methadone treatment as these two therapeutic aspects are likely to mitigate cognitive relationships. In contrast to the relationships between NC and the factors previously discussed, hepatitis C status was not a significant predictor of performance in any of the domains.

Given the complex medical and sociocultural contexts in which many urban HIV+ persons present to clinical research settings, and the reduction of the HIV signal due to the effectiveness of therapies, neuroAIDS investigators must continue to refine methods with which to manage confounds and advance knowledge in representative cohorts. Isolating the HIV signal is likely to continue to be a challenge as infected cohorts grow older and present with even more co-morbid conditions which create interpretive “noise” in HIV signal detection.

This study is limited by its design as a pilot and suffers from methodologic challenges such as low power and potential instability of the data related to the small sample size. However, the presence of statistically significant results, in the context of low power, makes the findings even more provocative. Future studies, with larger samples, should be completed to replicate these findings and test for potential interaction effects among variables of interest. This pilot study is further limited by the absence of non-drug using HIV+ and HIV- groups. Without “control” groups, we were unable to explore the independent influence of HIV and substance use as well as potential interactions between the two factors. Additionally, the HIV+ participants in this study were in the advanced stages of their disease, which may have exacerbated the degree of neurocognitive impairment, creating stronger effects than would be seen in other cohorts. Thus, the current findings may not generalize to a healthier cohort and should be replicated in other settings.

Acknowledgments

The authors gratefully acknowledge MHBB volunteers and research staff. Research supported by awards U01MH083501 from the National Institutes of Health, M01-RR-00071 from the Clinical Research Center of the Mount Sinai School of Medicine and by the Josiah Macy Foundation, Mount Sinai School of Medicine Center for Multicultural and Community Affairs.

References

- Baldewicz TT, Leserman J, Silva SG, Petitto J, Golden RN, Perkins DO, Evans DL. Changes in neuropsychological functioning with progression of HIV-1 infection: Results of an 8-year longitudinal investigation. *AIDS and Behavior*. 2004; 8(3):345–355. [PubMed: 15475681]
- Basso M, Bronstein R. Neurobehavioural consequences of substance abuse and HIV infection. *Psychopharmacology*. 2000; 14(3):228–237.
- Basso M, Bronstein R. Effects of past noninjection drug abuse upon executive function and working memory in HIV infection. *Journal of Clinical and Experimental Neuropsychology*. 2003; 25(7): 893–903. [PubMed: 13680438]
- Bell J, Arango J, Anthony I. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. *Journal of Neuroimmune Pharmacology*. 2006; 1(2):182–191. [PubMed: 18040783]
- Bell JE, Brettle RP, Chiswick AA, Simmonds PP. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS: Effect of neocortical involvement. *Brain*. 1998; 121(11): 2043–2052. [PubMed: 9827765]
- Bing E, Burnam M, Longshore D, Fleishman J, Sherbourne C, London A, Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. *Archives of General Psychiatry*. 2001; 58(8):721–728. [PubMed: 11483137]
- Brown E, Prager J, Lee H, Ramsey R. CNS complications of cocaine abuse: Prevalence, pathophysiology, and neuroradiology. *AJR American Journal of Roentgenology*. 1992; 159(1):137–147. [PubMed: 1609688]
- Burnam M, Bing E, Morton S, Sherbourne C, Fleishman J, London A, Shapiro M. Use of mental health and substance abuse treatment services among adults with HIV in the United States. *Archives of General Psychiatry*. 2001; 58(8):729–736. [PubMed: 11483138]
- Buttner A. Review: The neuropathology of drug abuse. *Neuropathology and Applied Neurobiology*. 2011; 37(2):118–134. [PubMed: 20946118]
- Byrd D, Fellows R, Morgello S, Franklin D, Heaton R, Deutsch R, Grant I. Neurocognitive impact of substance use in HIV infection. *Journal of Acquired Immune Deficiency Syndromes*. 2011; 58(2): 154–162. [PubMed: 21725250]
- Centers for Disease Control and Prevention(CDC). HIV prevalence among selected populations: High-risk populations. Retrieved from CDC Website http://www.cdc.gov/hiv/topics/testing/resources/reports/hiv_prevalence/high-risk.htm
- Chana G, Everall I, Crews L, Langford D, Adame A, Grant I, Masliah E. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. *Neurology*. 2006; 67(8):1486–1489. [PubMed: 17060582]
- Concha M, Graham N, Muñoz A, Vlahov D, Royal W, Updike M, McArthur J. Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. *American Journal of Epidemiology*. 1992; 136(11):1338–1348. [PubMed: 1362630]
- Concha M, Selnes OA, Vlahov D, Nance-Sproson T, Updike M, Royal W, McArthur JC. Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men. *Neuroepidemiology*. 1997; 16(2):78–85. [PubMed: 9057169]
- Darke S, McDonald S, Kaye S, Torok M. Comparative patterns of cognitive performance amongst opioid maintenance patients, abstinent opioid users and non-opioid users. *Drug and Alcohol Dependence*. 2012; 126:309–315. [PubMed: 22726911]

- Del Pesce M, Franciolini B, Censori B, Bartolini M, Ancarani F, Petrelli E, Provinciali L. Cognitive behavior in asymptomatic (CDC stage II and III) HIV-seropositive intravenous drug users (IVDUs). *Italian Journal of Neurological Sciences*. 1993; 4(9):619–625. [PubMed: 8125764]
- Devlin KN, Gongvatana A, Clark US, Chasman JD, Westbrook ML, Tashima KT, Cohen RA. Neurocognitive effects of HIV, hepatitis C, and substance use history. *Journal of The International Neuropsychological Society*. 2012; 18(1):68–78. [PubMed: 22132928]
- Durvasula R, Myers H, Satz P, Miller E, Morgenstern H, Richardson M, Forney D. HIV-1, cocaine, and neuropsychological performance in African American men. *Journal of the International Neuropsychological Society*. 2000; 6(3):322–335. [PubMed: 10824504]
- Fellows RP, Byrd DA, Elliott K, Robinson-Papp J, Rivera Mindt M, Morgello S. Distal sensory polyneuropathy is associated with neuropsychological test performance among persons with HIV. *Journal of the International Neuropsychological Society*. 2012; 19:1–10. [PubMed: 23095177]
- Fernández-Serrano M, Pérez-García M, Río-Valle J, Verdejo-García A. Neuropsychological consequences of alcohol and drug abuse on different components of executive functions. *Journal of Psychopharmacology*. 2010; 24(9):1317–1332. [PubMed: 20007413]
- Friedman H, Newton C, Klein T. Microbial infections, immunomodulation, and drugs of abuse. *Clinical Microbiology Reviews*. 2003; 16(2):209–219. [PubMed: 12692094]
- Garavan H, Kaufman J, Hester R. Acute effects of cocaine on the neurobiology of cognitive control. *Philosophical Transactions of the Royal Society of London B: Biological Sciences*. 2008; 363(1507):3267–3276.
- Gonzalez R, Cherner M. Co-factors in HIV neuro-behavioural disturbances: Substance abuse, hepatitis C and aging. *International Review of Psychiatry*. 2008; 20(1):49–60. [PubMed: 18240062]
- Gruber S, Silveri M, Yurgelun-Todd D. Neuropsychological consequences of opiate use. *Neuropsychology Review*. 2007; 17(3):299–315. [PubMed: 17690984]
- Hasin D, Trautman K, Miele G, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): Reliability for substance abusers. *The American Journal of Psychiatry*. 1996; 153(9):1195–1201. [PubMed: 8780425]
- Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake CC, Vaida FF, Grant II. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter study. *Neurology*. 2010; 75(23):2087–2096. [PubMed: 21135382]
- Janssen RS, Cornblath DR, Epstein LG, Foa RP. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a working group of the American Academy of Neurology AIDS task force. *Neurology*. 1991; 41:778–785. [PubMed: 2046917]
- Kalechstein, A.; van Gorp, W., editors. *Neuropsychology and substance use: State of the art and future directions*. Philadelphia, PA: Taylor & Francis; 2007.
- Koike H, Iijima M, Sugiura M, Mori K, Hattori N, Ito H, Sobue G. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. *Annals of Neurology*. 2003; 54(1):19–29. [PubMed: 12838517]
- Levine AJ, Hardy DJ, Miller E, Castellon SA, Longshore D, Hinkin CH. The effect of recent stimulant use on sustained attention in HIV-infected adults. *Journal of Clinical and Experimental Neuropsychology*. 2006; 28(1):29–42. [PubMed: 16448974]
- Liu H, Hao Y, Kaneko Y, Ouyang X, Zhang Y, Xu L, Liu Z. Frontal and cingulate gray matter volume reduction in heroin dependence: Optimized voxel-based morphometry. *Psychiatry and Clinical Neurosciences*. 2009; 63(4):563–568. [PubMed: 19531112]
- Llorente AM, Miller EN, D'Elia LF, Selnes OA, Wesch J, Becker JT, Satz P. Slowed information processing in HIV-1 disease. *Journal of Clinical and Experimental Neuropsychology*. 1998; 20(1):60–72.
- Lundqvist T. Imaging cognitive deficits in drug abuse. *Current Topics in Behavioral Neurosciences*. 2010; 3:247–275. [PubMed: 21161756]
- Manly JJ, Byrd D, Touradji P, Sanchez D, Stern Y. Literacy and cognitive change among ethnically diverse elders. *International Journal of Psychology*. 2004; 39(1):47–60.

- Manly JJ, Jacobs DM, Sano M, Bell K, Merchant CA, Small SA, Stern Y. Cognitive test performance among nondemented elderly African Americans and Whites. *Neurology*. 1998; 50:1238–1245. [PubMed: 9595969]
- Manly JJ, Jacobs D, Touradji P, Small S, Stern Y. Reading level attenuates differences in neuropsychological test performance between African American and White elders. *Journal of the International Neuropsychological Society*. 2002; 8:341–348. [PubMed: 11939693]
- Martin EM, Pitrak DL, Rains N, Grbesic S, Pursell K, Nunnally G, Bechara A. Delayed nonmatch-to-sample performance in HIV-seropositive and HIV-seronegative polydrug abusers. *Neuropsychology*. 2003; 17(2):283–288. [PubMed: 12803434]
- Martin-Thormeyer E, Paul R. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: Neurocognitive and neuroimaging features. *Neuropsychology Review*. 2009; 19(2):215–231. [PubMed: 19468837]
- Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. *Drug and Alcohol Dependence*. 2002; 67(1):41–51. [PubMed: 12062778]
- Mintzer MZ, Copersino ML, Stitzer ML. Opioid abuse and cognitive performance. *Drug and Alcohol Dependence*. 2005; 78(2):225–230. [PubMed: 15845327]
- Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, Sharp V. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank. *Archives of Neurology*. 2004; 61(4):546–551. [PubMed: 15096404]
- National Institute on Drug Abuse(NIDA). NIDA infofacts: Drug abuse and the link to HIV/AIDS and other infectious diseases. 2011 Jul. Retrieved from NIDA Website:<http://www.drugabuse.gov/sites/default/files/drugaids.pdf>
- Navia B, Jordan B, Price R. The AIDS dementia complex: I. Clinical features. *Annals of Neurology*. 1986; 19(6):517–524. [PubMed: 3729308]
- Neiman J, Haapaniemi H, Hillbom M. Neurological complications of drug abuse: Pathophysiological mechanisms. *European Journal of Neurology*. 2000; 7(6):595–606. [PubMed: 11136345]
- Pace-Schott E, Morgan PT, Malison RT, Hart CL, Edgar C, Walker M, Stickgold R. Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence. *The American Journal of Drug and Alcohol Abuse*. 2008; 34:109–121. [PubMed: 18161649]
- Poon HF, Abdullah L, Mullan MA, Crawford FC. Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. *Neurochemistry International*. 2007; 50:69–73. [PubMed: 16956698]
- Reger M, Welsh R, Razani J, Martin DJ, Boone KB. A meta-analysis of the neuropsychological sequelae of HIV infection. *Journal of the International Neuropsychological Society*. 2002; 8:410–424. [PubMed: 11939699]
- Reinhard MJ, Hinkin CH, Barclay TR, Levine AJ, Marion S, Castellon SA, Myers H. Discrepancies between self-report and objective measures for stimulant drug use in HIV: Cognitive medication adherence and psychological correlates. *Addictive Behaviors*. 2007; 32(12):2727–2736. [PubMed: 17499443]
- Richter R, Pearson J, Bruun B, Challenor Y, Brust J, Baden M. Neurological complications of addiction to heroin. *Bulletin of the New York Academy of Medicine*. 1973; 49(1):3–21. [PubMed: 4344820]
- Rippeth J, Heaton R, Carey C, Marcotte T, Moore D, Gonzalez R, et al. Grant I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. *Journal of the International Neuropsychological Society*. 2004; 10(1):1–14. [PubMed: 14751002]
- Robinson-Papp J, Byrd D, Rivera Mindt M, Oden NL, Cohen G, Simpson DM, Morgello S. for the Manhattan HIV Brain Bank Motor function and HIV-associated cognitive impairment in a HAART era cohort. *Archives of Neurology*. 2008; 65(8):1096–1101. [PubMed: 18695060]
- Ryan E, Baird R, Mindt M, Byrd D, Monzones J, Bank S. Neuropsychological impairment in racial/ethnic minorities with HIV infection and low literacy levels: Effects of education and reading level in participant characterization. *Journal of the International Neuropsychological Society*. 2005; 11(7):889–898. [PubMed: 16519268]

- Schlaepfer TE, Lancaster E, Heidbreder R, Strain EC, Kosel M, Fisch HU, Pearlson GD. Decreased frontal white-matter volume in chronic substance abuse. *International Journal of Neuropsychopharmacology*. 2006; 9:147–153.
- Scott J, Woods S, Matt G, Meyer R, Heaton R, Atkinson J, Grant I. Neurocognitive effects of methamphetamine: A critical review and meta-analysis. *Neuropsychology Review*. 2007; 17(3): 275–297. [PubMed: 17694436]
- Selnes O, Galai N, McArthur J, Cohn S, Royal W, Esposito D, Vlahov D. HIV infection and cognition in intravenous drug users: Long-term follow-up. *Neurology*. 1997; 48(1):223–230. [PubMed: 9008522]
- Soyka M, Lieb M, Kagerer S, Zingg C, Koller G, Lehnert P, Hennig-Fast K. Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial. *Journal of Clinical Psychopharmacology*. 2008; 28(6):699–703. [PubMed: 19011441]
- Venkatesan A, Nath A, Ming GI, Song H. Adult hippocampal neurogenesis: Regulation by HIV and drugs of abuse. *Cellular and Molecular Life Sciences*. 2007; 64(16):2120–2132. [PubMed: 17530169]
- Verdejo A, Toribio Y, Orozco C, Puente K, Pérez-García M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. *Drug and Alcohol Dependence*. 2005; 78(3):283–288. [PubMed: 15893159]
- Yuan Y, Zhu Z, Shi J, Zou Z, Yuan F, Liu Y, Weng X. Gray matter density negatively correlates with duration of heroin use in young lifetime heroin-dependent individuals. *Brain and Cognition*. 2009; 71(3):223–228. [PubMed: 19775795]
- Wiegmann DA, Stanny RR, McKay DL, Neri DF, McCardie AH. Methamphetamine effects on cognitive processing during extended wakefulness. *International Journal of Aviation Psychology*. 1996; 6(4):379–397. [PubMed: 11540403]
- Welch KA. Neurological complications of alcohol and misuse of drugs. *Practical Neurology*. 2011; 11:206–219. [PubMed: 21746706]
- Woods S, Rippeth J, Frol A, Levy J, Ryan E, Soukup V, Heaton R. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. *Journal of Clinical and Experimental Neuropsychology*. 2004; 26(6):759–778. [PubMed: 15370374]
- Wojna V, Nath A. Challenges to the diagnosis and management of HIV dementia. *The AIDS Reader*. 2006; 16(11):615–616. [PubMed: 17152649]
- Yeung M, Bhalla A, Birns J. Recreational drug misuse and stroke. *Current Drug Abuse Reviews*. 2011; 4(4):286–291. [PubMed: 22150621]

Table 1
Neuropsychological test battery and normative data

Neuropsychological domain and tests	Normative data sources
Reading level	
Wide Range Achievement Test, 3 rd Edition, Reading Recognition subtest	Wilkinson (1993) ¹
Abstraction/Executive Functioning	
Wisconsin Card Sorting Task-64 Item Version	Kongs, Thompson, Iverson & Heaton (2000) ^{1,2}
Trail Making Test (Part B)	Heaton, Grant & Matthews (1991) ^{1,2,3}
Attention/Working Memory	
WAIS-III Letter Number Sequencing	Wechsler (1997) ¹
PASAT Total Correct	Diehr et al. (2003) ^{1,2,3,4}
Learning	
Hopkins Verbal Learning Test-Revised (Total Recall)	Benedict, Schretlen, Groninger & Brandt (1998) ¹
Brief Visuospatial Memory Test-Revised (Total Recall)	Benedict (1997) ¹
Delayed Recall	
Hopkins Verbal Learning Test (Delayed Recall Trial)	Benedict, Schretlen, Groninger & Brandt (1998) ¹
Brief Visuospatial Memory Test-Revised (Delayed Recall Trial)	Benedict (1997) ¹
Motor	
Grooved Pegboard Time (dominant hand)	Heaton, Grant & Matthews (1991) ^{1,2,3}
Grooved Pegboard Time (non-dominant hand)	Heaton, Grant & Matthews (1991) ^{1,2,3}
Speed of Information Processing	
WAIS-III Digit Symbol	Wechsler (1997) ¹
WAIS-III Symbol Search	Wechsler (1997) ¹
Trail Making Test (Part A)	Heaton, Grant & Matthews (1991) ^{1,2,3}
Verbal Functioning	
Controlled Oral Word Association Test (F-A-S)	Gladsjo et al., 1999 ^{1,2,4}

Note: Wechsler Adult Intelligence Scale (WAIS); Paced Auditory Serial Arithmetic Test (PASAT). Normative data corrects for the following demographic characteristics indicated by superscript number:

¹ = age;

² = education;

³ = gender;

⁴ = ethnicity.

Table 2
Demographic and clinical characteristics

	HIV-(<i>n</i> = 30) Mean (<i>SD</i>) or %	HIV+ (<i>n</i> = 30) Mean (<i>SD</i>) or %
Age, years	47.8 (8.8)	46.4 (8.2)
% Female	67%	50%
% Ethnic minority	71%	83%
Education, years	11.5 (2.2)	11.5 (2.5)
WRAT-3 Reading Scaled Score	81.7 (16.4)	81.8 (16.7)
% w/hepatitis C	40%	59%
% Current methadone maintenance therapy	60%	60%
% + Utox illicit substances	57%	57%
Median viral load [range]	–	1413 [50- 684,578] undetectable = 25%
Median CD4 count [range]	–	166 [1-1,308] below 200 = 56.7%
% on HAART		63%

HAART = highly active antiretroviral therapy.

Table 3
Frequency of DSM-IV dependency diagnoses

	Past Dependence diagnosis <i>n</i> (%)		Current Dependence diagnosis <i>n</i> (%)	
	<i>HIV</i> -	<i>HIV</i> +	<i>HIV</i> -	<i>HIV</i> +
Alcohol	11 (36.7)	15 (50.0)	3 (10.0)	4 (13.3)
Cocaine	12 (40.0)	21 (70.0)	3 (10.0)	7 (23.3)
Cannabis	7 (23.3)	6 (20.0)	4 (13.3)	2 (6.7)
Opiate	16 (53.3)	21 (70.0)	4 (13.3)	7 (23.3)
Methamphetamine	0	0	0	0
Hallucinogen/ PCP	0	0	0	0
Sedative	0	0	1 (3.3)	1 (3.3)
Inhalant	0	0	0	0
Other drug	1 (3.33)	0	0	0

Table 4
Neuropsychological domain *t*-scores

	HIV-(<i>n</i> = 30) Mean (<i>SD</i>)	HIV+ (<i>n</i> = 30) Mean (<i>SD</i>)
Global	40.6 (7.4)	36.5 (7.5)
Motor	36.9 (10.1)	34.9 (7.6)
Processing Speed	46.0 (7.4)	39.6 (8.7)
Working Memory	45.0 (8.8)	41.8 (8.9)
Learning	34.4 (10.1)	28.9 (9.3)
Recall	34.7 (12.0)	30.3 (9.3)
Fluency	48.0 (11.9)	45.2 (11.2)
Abstraction	42.5 (8.2)	39.2 (8.5)

Table 5a
Regression analyses predicting Global and NC domain T-scores

	Global			Motor			Processing Speed		
	B	R ²	B	R ²	B	R ²	B	R ²	
Step 1 Control variables		.357**		.100				.122	
WRAT- 3 Reading	.265	.542**	.145	.262	.191		.349*		
Hepatitis C status	.380	.024	1.88	.105	-1.07		-.061		
Methadone treatment	-3.93	-.213 ⁺	-2.19	-2.121	-.802		-.045		
Positive urine tox	2.61	.166	.817	.045	.12		.007		
Step 2		.034*		.011			.111*		
HIV status	-3.94	-.251*	-1.92	-.107	-5.96		-.340*		

Note. Wide Range Achievement Test—Reading subtest, 3rd Edition.

* $p < .05$.

** $p < .01$.

⁺ $p < .10$.

Table 5b. Regression analyses predicting NC domain T-scores

	Working memory			Learning			Memory		
	B	R ²	B	R ²	B	R ²	B	R ²	
Step 1 Control variables		.258**		.389**				.495**	
WRAT- 3 Reading	.266	.468**	.309	.498**	.381		.573**		
Hepatitis C status	-.637	-.035	.010	.001	1.97		.092		
Methadone treatment	.079	.004	-6.25	-.309*	-8.14		-.376**		
Positive urine tox	4.11	.227 ⁺	5.66	.283*	4.17		.194 ⁺		
Step 2		.030		.066*			.038 ⁺		
HIV status	-3.22	-.179	-5.22	-.262*	-4.27		-.200 ⁺		

Note. Wide Range Achievement Test – Reading subtest, 3rd Edition.

* $p < .05$.

** $p < .01$.

Table 5b. Regression analyses predicting NC domain T-scores

	Working memory		Learning		Memory	
	B	R ²	B	R ²	B	R ²

[†] $p < .10$.

Table 5c. Regression analyses predicting NC domain T-scores

	Verbal Fluency		Executive Functioning		R ²
	b	R ²	B	R ²	
Step 1 Control variables		.261 ^{**}			.182 [*]
WRAT- 3 reading	.308	.441 ^{**}	.227	.413 ^{**}	
Hepatitis C status	1.52	.044	-1.41	-.042	
Methadone treatment	-6.39	-.269 [*]	-1.05	-.080	
Positive urine tox	1.57	.077	1.22	.061	
Step 2					.037
HIV	-2.75	-.121	-3.36	-.196	

Note. Wide Range Achievement Test – Reading subtest, 3rd Edition.

* $p < .05$.

** $p < .01$.

Table 6
Rates of impairment by HDMS domain

	HIV-(<i>n</i> = 30) % impaired	HIV+ (<i>n</i> =30) % impaired
Strength	3.3%	23.3%
Tone	0	3%
Reflexes	30%	53.3%
Coordination	3.3%	26.7%
Gait	16.7%	30%

Table 7a

Neurocognitive test performance for HIV+ motor groups

	HIV+ Motor normal (n=10)	HIV+ Motor impaired (n=20)	p value	η^2	Power
	Mean (SD)	Mean (SD)			
Motor	39.1 (7.3)	32.8 (7.0)	.06	.12	.45
Processing Speed	46.0 (7.0)	36.5 (7.8)	.007	.24	.79
Working Memory	43.5 (10.9)	40.9 (7.8)	.87	.001	.05
Learning	33.4 (9.9)	26.6 (8.3)	.18	.03	.14
Recall	34.1 (10.2)	28.5 (8.4)	.39	.03	.13
Fluency	52.9 (11.5)	41.3 (8.9)	.03	.16	.58
Abstraction	45.4 (6.3)	36.1 (7.9)	.01	.22	.75

Table 7b. Neurocognitive test performance for HIV- motor groups

	HIV- Motor normal (n=16)	HIV- Motor impaired (n=14)	p value	η^2	Power
	Mean (SD)	Mean (SD)			
Motor	36.9 (12.0)	36.9 (7.7)	.74	.005	.06
Processing Speed	45.4 (6.9)	46.7 (8.2)	.88	.001	.05
Working Memory	46.3 (6.9)	43.6 (10.5)	.34	.04	.14
Learning	32.6 (10.1)	36.4 (10.2)	.38	.01	.07
Recall	34.1 (12.1)	35.4 (11.5)	.97	.15	.07
Fluency	48.7 (10.8)	47.3 (13.3)	.68	.15	.07
Abstraction	42.1 (9.6)	43.0 (6.5)	.95	.003	.05